Table 2.
Controlled trials and selected observational data sets reporting sinus rhythm rates after catheter ablation of persistent atrial fibrillation
| Patients | Intervention | Control | Sinus rhythm outcome |
||
|---|---|---|---|---|---|
| Ablation | Control | ||||
| Controlled trials | |||||
| Wazni47 | 70 (paroxysmal and persistent) | CA | AAD + CV | 87%a | 46%a |
| Oral48 | 146 | PVI + Amiodarone | Amiodarone + CV | 74%a | 58%a |
| Stabile49 | 137 (paroxysmal or persistent) | CA: PVI + mitral line + CTI | AAD | 56% | 10% |
| Forleo50 | 70 (41 persistent) | CA | AAD + CV | 80%a | 43%a |
| Jones51 | 52 | CA | Rate control | 88%a | n.a. |
| Mont10 | 146 | CA | AAD + CV | 70% | 44% |
| Verma43 | 589 | PVI | PVI + lines, PVI + CFAE | 59% | 46%; 49% |
| Dong52 | 146 | CA + lines (fix) | CA (stepwise) | 67% | 60% |
| Observational data sets | |||||
| Hunter (multi centre)53 | 586 (persistent) | CA (1.8 mean procedures, mainly PVI) | n.a. | 60%a | n.a. |
| Scherr (single centre)54 | 150 | CA (AF termination outcome) | n.a. | 65% | n.a. |
| Schreiber (single centre)55 | 549 | CA (stepwise approach) | n.a. | 56% | n.a. |
| Haissaguerre56 | 103 | CA (driver domains) | 65%a | n.a. | |
AAD, antiarrhythmic drugs; CA, catheter ablation; CV, cardioversion; PVI, pulmonary vein isolation.
aNumbers in italic indicate success rates without intensive ECG monitoring.